Skip to main content

Table 5 Subgroup analysis of correlation between mRSS and pulmonary function by autoantibody profile or disease duration

From: Skin thickness score as a surrogate marker of organ involvements in systemic sclerosis: a retrospective observational study

 

Univariate analysis

Multivariate analysis

N

β (95% CI)

N

β (95% CI)

%FVC

 Autoantibody profile

  Anti-topo I Ab

65

− 0.68* (− 1.25 to − 0.11)

65

− 0.80** (− 1.39 to − 0.20)

  Anti-centromere Ab

60

− 1.36 (− 1.18 to 0.91)

  

  Anti-RNA polymerase III Ab

17

0.66 (− 0.29 to 1.61)

  

  Anti-U1RNP Ab

19

− 0.09 (− 1.07 to 0.89)

  

 Disease duration

  < 5 years

106

− 0.41* (− 0.77 to − 0.05)

106

− 0.43* (− 0.84 to − 0.02)

  ≥ 5 years

69

− 1.53*** (− 2.36 to − 0.70)

69

− 1.48** (− 2.33 to − 0.63)

%DLco

 Autoantibody profile

  Anti-topo I Ab

62

− 0.80** (− 1.36 to − 0.24)

53

− 0.68* (− 1.27 to − 0.08)

  Anti-centromere Ab

58

− 0.02 (− 1.02 to 1.07)

  

  Anti-RNA polymerase III Ab

17

− 0.07 (− 1.03 to 0.89)

  

  Anti-U1RNP Ab

19

− 0.63 (− 1.59 to 0.32)

  

 Disease duration

  < 5 years

104

− 0.70** (− 1.10 to − 0.30)

104

− 0.52* (− 0.97 to − 0.07)

  ≥ 5 years

66

− 0.86* (− 1.61 to − 0.11)

66

− 0.68 (− 1.43 to 0.06)

  1. N number of the observation, β regression coefficient, CI confidence interval. Asterisk (*) indicates statistical significance in regression analysis.*P < 0.05; **P < 0.01; ***P < 0.001